medigraphic.com
Colegio de Medicina Interna de México.

2018, Number 6

<< Back Next >>

Med Int Mex 2018; 34 (6)

Cardiometabolic effect of inhibitors of sodium glucose cotransporter type 2 (SGLT2)

García-Arias MR, Gonzaga-López TI, González-Fernández NC, Guzmán-Ramírez PM, Ángeles-Acuña A, Enríquez-Peregrino KG, Hintze-de León JC, Marín-Reyes AH, Cedillo-Rivera EA

Language: Spanish
References: 30
Page: 924-932
PDF size: 449.27 Kb.


ABSTRACT

There is an increase in the use of new drugs for the treatment of the different elements that integrate the metabolic syndrome; that, by their pharmacokinetics and pharmacodynamics have a pleiotropic effect. Recently, the inhibitors of sodium glucose cotransporter type 2 (SGLT2) used for the treatment of diabetes mellitus type 2 have demonstrated a cardio-renal protector effect. They function at the S1 segment of the proximal tube, lowering the filtration of glucose and enhancing its excretion; resulting in a glycosuric and natriuretic effect. This is the main mechanism of cardiovascular protection. Experimental essays and different studies, such as the EMAREG study and the CANVAS program, have established that the inhibitors of SGLT2 reduce the progression of hypertrophic cardiomyopathy, fibrosis, cardiac remodeling, systolic dysfunction and heart failure. The results of these studies recognize this group of drugs (empaglifozine and canaglifozine) as a valid treatment for cardiovascular protection in patients with diabetes mellitus type 2, and which is recommended by the FDA, the ACC/AHA, the European Society of Cardiology and the American Diabetes Association (ADA) in its last publication in 2018.


REFERENCES

  1. Tahrani AA, Barnett AH, Baile CJ. SGLT inhibitors in management of diabetes. Lancet 2013;1:140-151.

  2. DeFronzo R, Ferrannini E, Henry R, et al. Type 2 diabetes mellitus, Nature Reviews Disease Primers 2015;15019:1-22.

  3. DeFronzo RA. Banting lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009;58:773-795.

  4. Chao EC. SGLT-2 inhibitors: A new mechanism for glycemic control. Clinical Diabetes 2014 Jan; 32(1):4-11.

  5. Gustavson SM, et al. Effects of hyperglycemia, glucagon, and epinephrine on renal glucose release in the conscious dog. Metabolism 2004;53:933-941.

  6. Ehrenkranz RRL, Lewis NG, Kahn CR, Roth J. Phlorizin: a review. Diabetes Metab Res Rev 2005;21:31-38.

  7. DeFronzo R-A, Norton L, Abdul-Ghani M. Renal, metabolic and cardiovascular considerations of SGLT2 inhibition. Nature Reviews Nephrology 2016: 11-26.

  8. White JR. Apple trees to sodium glucose co-transport inhibitors: A review of SGLT2 inhibition. Clin Diabetes 2010;28:5-10.

  9. Abdul-Ghani MA, DeFronzo RA, Norton L. Novel hypothesis to explain why SGLT2 inhibitors inhibit only 30-50% of filtered glucose load in humans. Diabetes 2013;62:3324-3328.

  10. Mazidi M, Rezaie P, Gao HK, et al. Effect of sodium-glucose cotransport-2 inhibitors on blood pressure in people with type 2 diabetes mellitus: a systematic review and meta-analysis of 43 randomized control trials with 22 528 patients. J Am Heart Assoc 2017;6:e004007.

  11. Taylor SI, Blau JE, Rother KI. Possible adverse effects of SGLT2 inhibitors on bone. Lancet Diabetes Endocrinol 2015;3:8-10.

  12. Scheen AJ. SGLT2 inhibitors: benefit/risk balance. Curr Diab Rep 2016;16:92.

  13. Scheen AJ. Pharmacodynamics, efficacy and safety of sodium–glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus. Drugs 2015;75:33-59.

  14. Staels B. Cardiovascular protection by sodium glucose cotransporter 2 inhibitors: Potential mechanisms. Am J Med 2017;130:S30-S39.

  15. Packer M, Anker S, Butler J, et al. Effects of sodium-glucose cotransporter 2 inhibitors for the treatment of patients whit heart failure proposal of a novel mechanism of action. JAMA Cardiol 2017;2(9):1025-1029.

  16. Liu T, Takimoto E, Dimaano VL, et al. Inhibiting mitochondrial Na+/Ca2+ exchange prevents sudden death in a Guinea pig model of heart failure. Circ Res 2014;115:44-54.

  17. Fitchett D, Zinman B, Wanner C, et al. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME trial. Eur Heart J 2016;37:1526-1534.

  18. Volker V. The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus. Ann Rev Med 2015;66(1):255-270.

  19. Baartscheer A, Schumacher CA, Wüst RC, et al. Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits. Diabetologia 2017;60(3):568-573.

  20. Baker WL, Buckley LF, Kelly MS, et al. Effects of sodiumglucose cotransporter 2 inhibitors on 24-hour ambulatory blood pressure: a systematic review and meta-analysis. J Am Heart Assoc 2017;6:e005686.

  21. Zinman B, Wanner C, Lachin JM, et al. EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373:2117-2128.

  22. Rastogui A, Bhansali A, SGLT2 inhibitors through the windows of EMPA-REG and CANVAS trials: A Review. Diabetes Ther. 2017 Dec; 8(6): 1245–1251.

  23. Xie X, Atkins E, Lv J, et al. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. Lancet 2016;387:435-443.

  24. Abdul-Ghani M, Del Peato S, Chilton R, DeFronzo R. SGLT2 inhibitors and cardiovascular risk: Lessons learned from the EMPA-REG OUTCOME Study. Diabetes Care 2016;39:717-72.

  25. Neal B, Perkovic V, Mahaffey KW, et al. CANVAS Program Collaborative Group. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017;377:644- 657.

  26. Cardiovascular disease and risk management: Standards of medical care in diabetes. Diabetes Care 2018;41(Suppl. 1):S86-S10.

  27. Mudaliar S, Alloju S, Henry RR. Can a shift in fuel energetics explain the beneficial cardiorenal outcomes in the EMPAREG OUTCOME study? A unifying hypothesis. Diabetes Care 2016;39:1115-1122.

  28. Verma S, McMurray J, Cherney D. The metabolodiuretic promise of sodium dependent glucose cotransporter 2 inhibition. The search for the sweet spot in heart failure. JAMA Cardiol 2017;2(9):939-940.

  29. Lytvyn Y, Bjornstad P, Udell J, et al. Sodium glucose cotransporter-2 inhibition in heart failure. Circulation 2017;136:1643-1658.

  30. Scheen AJ. Cardiovascular effects of new oral glucoselowering agents DPP-4 and SGLT-2 inhibitors. Circ Res 2018;122:1439-1459.




2020     |     www.medigraphic.com